ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Grunenthal: Vimovo™ Transition (PIP: 3591088) 30th November 2020

Manufacturer Agreements

30.11.2020

Grunenthal: Vimovo™ Transition (PIP: 3591088) 30th November 2020

On the 30th November 2020, the Marketing Authorisation for Vimovo™ 500mg/ 20mg modified release tablets (500mg naproxen/ 20mg esomeprazole) transferred from AstraZeneca to Grunenthal. As Alliance Healthcare is Grunenthal’s exclusive wholesale partner this line will only be available to purchase from Alliance Healthcare moving forward. The applicable 5% downstream discount on selected Grunenthal lines will be applied to Vimovo™. If you have any queries, please speak to your Alliance Healthcare Account Manager.